Qualicenters - Bend Llc is a medicare approved dialysis facility center in Bend, Oregon and it has 17 dialysis stations. It is located in Deschutes county at 1239 Ne Medical Center Dr Ste 100, Bend, OR, 97701. You can reach out to the office of Qualicenters - Bend Llc at (541) 385-8668. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Qualicenters - Bend Llc has the following ownership type - Profit. It was first certified by medicare in June, 1995. The medicare id for this facility is 382518 and it accepts patients under medicare ESRD program.
| Name | Qualicenters - Bend Llc |
|---|---|
| Location | 1239 Ne Medical Center Dr Ste 100, Bend, Oregon |
| No. of Dialysis Stations | 17 |
| Medicare ID | 382518 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 1239 Ne Medical Center Dr Ste 100, Bend, Oregon, 97701 | |
| (541) 385-8668 | |
News Archive
Janssen R&D Ireland (Janssen) announced today that two Phase 3 trials are recruiting patients to examine the efficacy and safety of the NS3/4A protease inhibitor simeprevir in combination with the nucleotide inhibitor sofosbuvir for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection in treatment-naive and treatment-experienced patients with and without cirrhosis.
Researchers at the SUNY Upstate Medical University have found that a key cellular enzyme, c-Abl, could be an effective drug target in cancer cells for urologic cancers, such as prostate and kidney.
InterMune, Inc. (Nasdaq: ITMN) today announced that it will be collaborating with National Jewish Health(R)( )investigators in order to help further the research of inherited genetic factors that may play a role in idiopathic pulmonary fibrosis (IPF). InterMune will provide researchers at National Jewish with access to DNA collected from patients who participated in the Company's Phase 3 clinical trials in IPF for both pirfenidone (CAPACITY trials) and Actimmune(R) (interferon gamma-1b) (INSPIRE).
Erythropoietin helps to protect and repair vulnerable brains though it remains a mystery how the anemia drug does so.
› Verified 5 days ago
| NPI Number | 1376655175 |
| Organization Name | Fresenius Medical Care Bend |
| Doing Business As | Qualicenters Bend Llc |
| Address | 1239 Ne Medical Center Dr Bend, Oregon, 97701 |
| Phone Number | (541) 385-8668 |
News Archive
Janssen R&D Ireland (Janssen) announced today that two Phase 3 trials are recruiting patients to examine the efficacy and safety of the NS3/4A protease inhibitor simeprevir in combination with the nucleotide inhibitor sofosbuvir for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection in treatment-naive and treatment-experienced patients with and without cirrhosis.
Researchers at the SUNY Upstate Medical University have found that a key cellular enzyme, c-Abl, could be an effective drug target in cancer cells for urologic cancers, such as prostate and kidney.
InterMune, Inc. (Nasdaq: ITMN) today announced that it will be collaborating with National Jewish Health(R)( )investigators in order to help further the research of inherited genetic factors that may play a role in idiopathic pulmonary fibrosis (IPF). InterMune will provide researchers at National Jewish with access to DNA collected from patients who participated in the Company's Phase 3 clinical trials in IPF for both pirfenidone (CAPACITY trials) and Actimmune(R) (interferon gamma-1b) (INSPIRE).
Erythropoietin helps to protect and repair vulnerable brains though it remains a mystery how the anemia drug does so.
› Verified 5 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 75% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 16% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 9% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 80% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 16% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 4% | 14% |
News Archive
Janssen R&D Ireland (Janssen) announced today that two Phase 3 trials are recruiting patients to examine the efficacy and safety of the NS3/4A protease inhibitor simeprevir in combination with the nucleotide inhibitor sofosbuvir for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection in treatment-naive and treatment-experienced patients with and without cirrhosis.
Researchers at the SUNY Upstate Medical University have found that a key cellular enzyme, c-Abl, could be an effective drug target in cancer cells for urologic cancers, such as prostate and kidney.
InterMune, Inc. (Nasdaq: ITMN) today announced that it will be collaborating with National Jewish Health(R)( )investigators in order to help further the research of inherited genetic factors that may play a role in idiopathic pulmonary fibrosis (IPF). InterMune will provide researchers at National Jewish with access to DNA collected from patients who participated in the Company's Phase 3 clinical trials in IPF for both pirfenidone (CAPACITY trials) and Actimmune(R) (interferon gamma-1b) (INSPIRE).
Erythropoietin helps to protect and repair vulnerable brains though it remains a mystery how the anemia drug does so.
› Verified 5 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 63% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 19% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 18% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 66% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 29% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 5% | 12% |
News Archive
Janssen R&D Ireland (Janssen) announced today that two Phase 3 trials are recruiting patients to examine the efficacy and safety of the NS3/4A protease inhibitor simeprevir in combination with the nucleotide inhibitor sofosbuvir for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection in treatment-naive and treatment-experienced patients with and without cirrhosis.
Researchers at the SUNY Upstate Medical University have found that a key cellular enzyme, c-Abl, could be an effective drug target in cancer cells for urologic cancers, such as prostate and kidney.
InterMune, Inc. (Nasdaq: ITMN) today announced that it will be collaborating with National Jewish Health(R)( )investigators in order to help further the research of inherited genetic factors that may play a role in idiopathic pulmonary fibrosis (IPF). InterMune will provide researchers at National Jewish with access to DNA collected from patients who participated in the Company's Phase 3 clinical trials in IPF for both pirfenidone (CAPACITY trials) and Actimmune(R) (interferon gamma-1b) (INSPIRE).
Erythropoietin helps to protect and repair vulnerable brains though it remains a mystery how the anemia drug does so.
› Verified 5 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 90% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 10% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 65% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 29% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 6% | 12% |
News Archive
Janssen R&D Ireland (Janssen) announced today that two Phase 3 trials are recruiting patients to examine the efficacy and safety of the NS3/4A protease inhibitor simeprevir in combination with the nucleotide inhibitor sofosbuvir for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection in treatment-naive and treatment-experienced patients with and without cirrhosis.
Researchers at the SUNY Upstate Medical University have found that a key cellular enzyme, c-Abl, could be an effective drug target in cancer cells for urologic cancers, such as prostate and kidney.
InterMune, Inc. (Nasdaq: ITMN) today announced that it will be collaborating with National Jewish Health(R)( )investigators in order to help further the research of inherited genetic factors that may play a role in idiopathic pulmonary fibrosis (IPF). InterMune will provide researchers at National Jewish with access to DNA collected from patients who participated in the Company's Phase 3 clinical trials in IPF for both pirfenidone (CAPACITY trials) and Actimmune(R) (interferon gamma-1b) (INSPIRE).
Erythropoietin helps to protect and repair vulnerable brains though it remains a mystery how the anemia drug does so.
› Verified 5 days ago
| Dialysis patients with Hemoglobin data | 61 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 18 |
News Archive
Janssen R&D Ireland (Janssen) announced today that two Phase 3 trials are recruiting patients to examine the efficacy and safety of the NS3/4A protease inhibitor simeprevir in combination with the nucleotide inhibitor sofosbuvir for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection in treatment-naive and treatment-experienced patients with and without cirrhosis.
Researchers at the SUNY Upstate Medical University have found that a key cellular enzyme, c-Abl, could be an effective drug target in cancer cells for urologic cancers, such as prostate and kidney.
InterMune, Inc. (Nasdaq: ITMN) today announced that it will be collaborating with National Jewish Health(R)( )investigators in order to help further the research of inherited genetic factors that may play a role in idiopathic pulmonary fibrosis (IPF). InterMune will provide researchers at National Jewish with access to DNA collected from patients who participated in the Company's Phase 3 clinical trials in IPF for both pirfenidone (CAPACITY trials) and Actimmune(R) (interferon gamma-1b) (INSPIRE).
Erythropoietin helps to protect and repair vulnerable brains though it remains a mystery how the anemia drug does so.
› Verified 5 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 88 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 732 |
| Percentage of adult patients getting regular hemodialysis at the center | 95 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Janssen R&D Ireland (Janssen) announced today that two Phase 3 trials are recruiting patients to examine the efficacy and safety of the NS3/4A protease inhibitor simeprevir in combination with the nucleotide inhibitor sofosbuvir for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection in treatment-naive and treatment-experienced patients with and without cirrhosis.
Researchers at the SUNY Upstate Medical University have found that a key cellular enzyme, c-Abl, could be an effective drug target in cancer cells for urologic cancers, such as prostate and kidney.
InterMune, Inc. (Nasdaq: ITMN) today announced that it will be collaborating with National Jewish Health(R)( )investigators in order to help further the research of inherited genetic factors that may play a role in idiopathic pulmonary fibrosis (IPF). InterMune will provide researchers at National Jewish with access to DNA collected from patients who participated in the Company's Phase 3 clinical trials in IPF for both pirfenidone (CAPACITY trials) and Actimmune(R) (interferon gamma-1b) (INSPIRE).
Erythropoietin helps to protect and repair vulnerable brains though it remains a mystery how the anemia drug does so.
› Verified 5 days ago
| Adult patients getting regular peritoneal dialysis at the center | 54 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 410 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 97 |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
Janssen R&D Ireland (Janssen) announced today that two Phase 3 trials are recruiting patients to examine the efficacy and safety of the NS3/4A protease inhibitor simeprevir in combination with the nucleotide inhibitor sofosbuvir for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection in treatment-naive and treatment-experienced patients with and without cirrhosis.
Researchers at the SUNY Upstate Medical University have found that a key cellular enzyme, c-Abl, could be an effective drug target in cancer cells for urologic cancers, such as prostate and kidney.
InterMune, Inc. (Nasdaq: ITMN) today announced that it will be collaborating with National Jewish Health(R)( )investigators in order to help further the research of inherited genetic factors that may play a role in idiopathic pulmonary fibrosis (IPF). InterMune will provide researchers at National Jewish with access to DNA collected from patients who participated in the Company's Phase 3 clinical trials in IPF for both pirfenidone (CAPACITY trials) and Actimmune(R) (interferon gamma-1b) (INSPIRE).
Erythropoietin helps to protect and repair vulnerable brains though it remains a mystery how the anemia drug does so.
› Verified 5 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Qualicenters - Bend Llc with elevated calcium levels.
| Patients with hypercalcemia | 142 |
| Hypercalcemia patient months | 1226 |
| Patients with Serumphosphor | 152 |
| Patients with Serumphosphor less than 3.5 mg/dL | 8 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 29 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 30 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 24 |
| Patients with Serumphosphor greater than 7 mg/dL | 10 |
News Archive
Janssen R&D Ireland (Janssen) announced today that two Phase 3 trials are recruiting patients to examine the efficacy and safety of the NS3/4A protease inhibitor simeprevir in combination with the nucleotide inhibitor sofosbuvir for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection in treatment-naive and treatment-experienced patients with and without cirrhosis.
Researchers at the SUNY Upstate Medical University have found that a key cellular enzyme, c-Abl, could be an effective drug target in cancer cells for urologic cancers, such as prostate and kidney.
InterMune, Inc. (Nasdaq: ITMN) today announced that it will be collaborating with National Jewish Health(R)( )investigators in order to help further the research of inherited genetic factors that may play a role in idiopathic pulmonary fibrosis (IPF). InterMune will provide researchers at National Jewish with access to DNA collected from patients who participated in the Company's Phase 3 clinical trials in IPF for both pirfenidone (CAPACITY trials) and Actimmune(R) (interferon gamma-1b) (INSPIRE).
Erythropoietin helps to protect and repair vulnerable brains though it remains a mystery how the anemia drug does so.
› Verified 5 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 91 |
| Patient months included in arterial venous fistula and catheter summaries | 688 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 80 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 5 |
News Archive
Janssen R&D Ireland (Janssen) announced today that two Phase 3 trials are recruiting patients to examine the efficacy and safety of the NS3/4A protease inhibitor simeprevir in combination with the nucleotide inhibitor sofosbuvir for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection in treatment-naive and treatment-experienced patients with and without cirrhosis.
Researchers at the SUNY Upstate Medical University have found that a key cellular enzyme, c-Abl, could be an effective drug target in cancer cells for urologic cancers, such as prostate and kidney.
InterMune, Inc. (Nasdaq: ITMN) today announced that it will be collaborating with National Jewish Health(R)( )investigators in order to help further the research of inherited genetic factors that may play a role in idiopathic pulmonary fibrosis (IPF). InterMune will provide researchers at National Jewish with access to DNA collected from patients who participated in the Company's Phase 3 clinical trials in IPF for both pirfenidone (CAPACITY trials) and Actimmune(R) (interferon gamma-1b) (INSPIRE).
Erythropoietin helps to protect and repair vulnerable brains though it remains a mystery how the anemia drug does so.
› Verified 5 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 131 |
| Hospitalization Rate in facility | 130.1 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 228.4 |
| Hospitalization Rate: Lower Confidence Limit | 80.6 |
News Archive
Janssen R&D Ireland (Janssen) announced today that two Phase 3 trials are recruiting patients to examine the efficacy and safety of the NS3/4A protease inhibitor simeprevir in combination with the nucleotide inhibitor sofosbuvir for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection in treatment-naive and treatment-experienced patients with and without cirrhosis.
Researchers at the SUNY Upstate Medical University have found that a key cellular enzyme, c-Abl, could be an effective drug target in cancer cells for urologic cancers, such as prostate and kidney.
InterMune, Inc. (Nasdaq: ITMN) today announced that it will be collaborating with National Jewish Health(R)( )investigators in order to help further the research of inherited genetic factors that may play a role in idiopathic pulmonary fibrosis (IPF). InterMune will provide researchers at National Jewish with access to DNA collected from patients who participated in the Company's Phase 3 clinical trials in IPF for both pirfenidone (CAPACITY trials) and Actimmune(R) (interferon gamma-1b) (INSPIRE).
Erythropoietin helps to protect and repair vulnerable brains though it remains a mystery how the anemia drug does so.
› Verified 5 days ago
The rate of readmission show you whether patients who were being treated regularly at Qualicenters - Bend Llc were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 23.6 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 33.5 |
| Readmission Rate: Lower Confidence Limit | 15.6 |
News Archive
Janssen R&D Ireland (Janssen) announced today that two Phase 3 trials are recruiting patients to examine the efficacy and safety of the NS3/4A protease inhibitor simeprevir in combination with the nucleotide inhibitor sofosbuvir for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection in treatment-naive and treatment-experienced patients with and without cirrhosis.
Researchers at the SUNY Upstate Medical University have found that a key cellular enzyme, c-Abl, could be an effective drug target in cancer cells for urologic cancers, such as prostate and kidney.
InterMune, Inc. (Nasdaq: ITMN) today announced that it will be collaborating with National Jewish Health(R)( )investigators in order to help further the research of inherited genetic factors that may play a role in idiopathic pulmonary fibrosis (IPF). InterMune will provide researchers at National Jewish with access to DNA collected from patients who participated in the Company's Phase 3 clinical trials in IPF for both pirfenidone (CAPACITY trials) and Actimmune(R) (interferon gamma-1b) (INSPIRE).
Erythropoietin helps to protect and repair vulnerable brains though it remains a mystery how the anemia drug does so.
› Verified 5 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Qualicenters - Bend Llc get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .74 (As Expected) |
| SIR: Upper Confidence Limit | 2.02 |
| SIR: Lower Confidence Limit | .19 |
News Archive
Janssen R&D Ireland (Janssen) announced today that two Phase 3 trials are recruiting patients to examine the efficacy and safety of the NS3/4A protease inhibitor simeprevir in combination with the nucleotide inhibitor sofosbuvir for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection in treatment-naive and treatment-experienced patients with and without cirrhosis.
Researchers at the SUNY Upstate Medical University have found that a key cellular enzyme, c-Abl, could be an effective drug target in cancer cells for urologic cancers, such as prostate and kidney.
InterMune, Inc. (Nasdaq: ITMN) today announced that it will be collaborating with National Jewish Health(R)( )investigators in order to help further the research of inherited genetic factors that may play a role in idiopathic pulmonary fibrosis (IPF). InterMune will provide researchers at National Jewish with access to DNA collected from patients who participated in the Company's Phase 3 clinical trials in IPF for both pirfenidone (CAPACITY trials) and Actimmune(R) (interferon gamma-1b) (INSPIRE).
Erythropoietin helps to protect and repair vulnerable brains though it remains a mystery how the anemia drug does so.
› Verified 5 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Qualicenters - Bend Llc's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 112 |
| Transfusion Rate in facility | 37.1 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 77.6 |
| Transfusion Rate: Lower Confidence Limit | 19.5 |
News Archive
Janssen R&D Ireland (Janssen) announced today that two Phase 3 trials are recruiting patients to examine the efficacy and safety of the NS3/4A protease inhibitor simeprevir in combination with the nucleotide inhibitor sofosbuvir for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection in treatment-naive and treatment-experienced patients with and without cirrhosis.
Researchers at the SUNY Upstate Medical University have found that a key cellular enzyme, c-Abl, could be an effective drug target in cancer cells for urologic cancers, such as prostate and kidney.
InterMune, Inc. (Nasdaq: ITMN) today announced that it will be collaborating with National Jewish Health(R)( )investigators in order to help further the research of inherited genetic factors that may play a role in idiopathic pulmonary fibrosis (IPF). InterMune will provide researchers at National Jewish with access to DNA collected from patients who participated in the Company's Phase 3 clinical trials in IPF for both pirfenidone (CAPACITY trials) and Actimmune(R) (interferon gamma-1b) (INSPIRE).
Erythropoietin helps to protect and repair vulnerable brains though it remains a mystery how the anemia drug does so.
› Verified 5 days ago
The rate of mortality show you whether patients who were being treated regularly at Qualicenters - Bend Llc lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 634 |
| Mortality Rate in facility | 16.5 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 20.5 |
| Mortality Rate: Lower Confidence Limit | 13.2 |
News Archive
Janssen R&D Ireland (Janssen) announced today that two Phase 3 trials are recruiting patients to examine the efficacy and safety of the NS3/4A protease inhibitor simeprevir in combination with the nucleotide inhibitor sofosbuvir for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection in treatment-naive and treatment-experienced patients with and without cirrhosis.
Researchers at the SUNY Upstate Medical University have found that a key cellular enzyme, c-Abl, could be an effective drug target in cancer cells for urologic cancers, such as prostate and kidney.
InterMune, Inc. (Nasdaq: ITMN) today announced that it will be collaborating with National Jewish Health(R)( )investigators in order to help further the research of inherited genetic factors that may play a role in idiopathic pulmonary fibrosis (IPF). InterMune will provide researchers at National Jewish with access to DNA collected from patients who participated in the Company's Phase 3 clinical trials in IPF for both pirfenidone (CAPACITY trials) and Actimmune(R) (interferon gamma-1b) (INSPIRE).
Erythropoietin helps to protect and repair vulnerable brains though it remains a mystery how the anemia drug does so.
› Verified 5 days ago
Qualicenters - Bend Llc Location: 1239 Ne Medical Center Dr Ste 100, Bend, Oregon, 97701 Phone: (541) 385-8668 |
News Archive
Janssen R&D Ireland (Janssen) announced today that two Phase 3 trials are recruiting patients to examine the efficacy and safety of the NS3/4A protease inhibitor simeprevir in combination with the nucleotide inhibitor sofosbuvir for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection in treatment-naive and treatment-experienced patients with and without cirrhosis.
Researchers at the SUNY Upstate Medical University have found that a key cellular enzyme, c-Abl, could be an effective drug target in cancer cells for urologic cancers, such as prostate and kidney.
InterMune, Inc. (Nasdaq: ITMN) today announced that it will be collaborating with National Jewish Health(R)( )investigators in order to help further the research of inherited genetic factors that may play a role in idiopathic pulmonary fibrosis (IPF). InterMune will provide researchers at National Jewish with access to DNA collected from patients who participated in the Company's Phase 3 clinical trials in IPF for both pirfenidone (CAPACITY trials) and Actimmune(R) (interferon gamma-1b) (INSPIRE).
Erythropoietin helps to protect and repair vulnerable brains though it remains a mystery how the anemia drug does so.
› Verified 5 days ago